Product Images Viibryd

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 11 images provide visual information about the product associated with Viibryd NDC 0456-1120 by Allergan, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

The structural formula for Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1). Its molecular weight is 477.99. - viibryd 01

The structural formula for Vilazodone HCl is 2-benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1). Its molecular weight is 477.99. - viibryd 01

Figure 1. Effect of Other Drugs on Vilazodone Pharmacokinetics - viibryd 02

Figure 1. Effect of Other Drugs on Vilazodone Pharmacokinetics - viibryd 02

This text seems to be presenting data related to changes in drug concentrations due to K Fold Change and 90% C1, with respect to different inhibitors. It mentions specific drugs and their maximum concentrations (Cmax) and average concentrations following the use of certain inhibitors. The text also makes reference to a graph or chart showing the changes, possibly over time.*

Figure 2. Impact of Vilazodone on Other Drug Pharmacokinetics - viibryd 03

Figure  2. Impact of Vilazodone on Other Drug Pharmacokinetics - viibryd 03

Figure 3: Impact of Intrinsic Factors on Vilazodone Pharmacokinetics - viibryd 04

Figure 3: Impact of Intrinsic Factors on Vilazodone Pharmacokinetics - viibryd 04

This is not-available. The text seems to be a combination of numerical values and random sentences that do not make any sense. It is not possible to generate a useful description using this text.*

viibryd 05

viibryd 05

Allergan Logo - viibryd 06

Allergan Logo - viibryd 06

NDC 0456-1110-30Viibrydvilazodone HCItablets30 Tablets10 mgRx Only - viibryd 07

NDC 0456-1110-30Viibrydvilazodone HCItablets30 Tablets10 mgRx Only - viibryd 07

Viibryd® is a medication containing 10 mg of vilazodone hydrochloride in tablet form. The usual recommended dosage is provided in the package insert, and the medication should be kept in a tightly closed container out of reach of children. Viibryd® is distributed by Allergan USA, Inc. and is a registered trademark. The medication is only available with a prescription and should be accompanied by a medication guide for each patient. The text also includes information on storage temperature ranges and the manufacturer's address.*

NDC 0456-1120-30Viibrydvilazodone HCItablets30 Tablets20 mgRx Only - viibryd 08

NDC 0456-1120-30Viibrydvilazodone HCItablets30 Tablets20 mgRx Only - viibryd 08

Viibryd is a medication used to treat major depression. Each bottle contains 30 tablets of 20 mg each. Dispense the accompanying medication guide to each patient. Viibryd is a registered trademark of Forest Laboratories LLC. The medicine is distributed by Allergan, a company located in Irvine, CA.*

NDC 0456-1140-30Viibrydvilazodone HCItablets30 Tablets40 mgRx Only - viibryd 09

NDC 0456-1140-30Viibrydvilazodone HCItablets30 Tablets40 mgRx Only - viibryd 09

This is a prescription medication called Viibryd. Each package contains 30 tablets that have 40 mg of vilazodone HCI. It is recommended to provide the medication guide to each patient who receives it.*

PRINCIPAL DISPLAY PANELNDC 0456-1100-31Viibrydvilazodone HCI tablets10 mgDays 1-720 mgDays 8-1440 mgDays 15-30Rx Only - viibryd 0a

PRINCIPAL DISPLAY PANELNDC 0456-1100-31Viibrydvilazodone HCI tablets10 mgDays 1-720 mgDays 8-1440 mgDays 15-30Rx Only - viibryd 0a

PRINCIPAL DISPLAY PANELNDC 0456-1101-30Viibrydvilazodone HCI tablets10 mgDays 1-720 mgDays 8-30Rx Only - viibryd 0b

PRINCIPAL DISPLAY PANELNDC 0456-1101-30Viibrydvilazodone HCI tablets10 mgDays 1-720 mgDays 8-30Rx Only - viibryd 0b

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.